AÑOS DE PUBLICACIÓN:
2019 || 2018 || 2017 || 2016 || 2015 || 2014 || 2013 || 2012 || 2011 || 2010 || 2009 || 2008 || 2007 |
2015
Multiplex phenotyping for systems medicine: A one-point optimized practical sampling strategy for simultaneous estimation of CYP1A2, CYP2C9, CYP2C19, and CYP2D6 activities using a cocktail approach.
de Andrés F, Terán S, Bovera M, Fariñas H, Terán E, LLerena A.
OMICS. 2016 Feb;20(2):88-96.
Worldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes.
Céspedes-Garro C, Fricke-Galindo I, Naranjo ME, Rodrigues-Soares F, FariñasH, de Andrés F, López-López M, Peñas-Lledó EM, LLerena A.
Expert Opin Drug Metab Toxicol. 2015;11(12):1893-905.
Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes across world populations.
Fricke-Galindo I, Céspedes-Garro C, Rodrigues-Soares F, Naranjo ME, Delgado Á, de Andrés F, López-López M, Peñas-Lledó E, LLerena A.
Pharmacogenomics J. 2016 Apr;16(2):113-23.
Metabolic phenotype prediction from genotyping data: a bottleneck for the implementation of pharmacogenetics in drug development and clinical practice.
LLerena A, Peñas-Lledó EM.
Drug Metab Pers Ther. 2015 Sep;30(3):143-5.
CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy.
Ortega-Vázquez A, Dorado P, Fricke-Galindo I, Jung-Cook H, Monroy-Jaramillo N, Martínez-Juárez IE, Familiar-López I, Peñas-Lledó E, LLerena A, López-López M.
Pharmacogenomics J. 2016 Jun;16(3):286-92.
Pharmacogenetics in Central American healthy volunteers: interethnic variability.
Céspedes-Garro C, Naranjo ME, Ramírez R, Serrano V, Fariñas H, Barrantes R, LLerena A; CEIBA Consortium of the Ibero-American Network of Pharmacogenetics andPharmacogenomics RIBEF.
Drug Metab Pers Ther. 2015 Mar;30(1):19-31.
High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme.
Apellániz-Ruiz M, Inglada-Pérez L, Naranjo ME, Sánchez L, Mancikova V, Currás-Freixes M, de Cubas AA, Comino-Méndez I, Triki S, Rebai A, Rasool M, Moya G, Grazina M, Opocher G, Cascón A, Taboada-Echalar P, Ingelman-Sundberg M, Carracedo A, Robledo M, Llerena A, Rodríguez-Antona C.
Pharmacogenomics J. 2015 Jun;15(3):288-92.
Success stories in genomic medicine from resource-limited countries.
Mitropoulos K, Al Jaibeji H, Forero DA, Laissue P, Wonkam A, Lopez-Correa C, Mohamed Z, Chantratita W, Lee MT, Llerena A, Brand A, Ali BR, Patrinos GP.
Hum Genomics. 2015 Jun 18;9:11.
Population pharmacogenetics and global health.
LLerena A.
Drug Metab Pers Ther. 2015 Jun;30(2):73-4.
Pharmacogenetics of adverse reactions to antiepileptic drugs.
Fricke-Galindo I, Jung-Cook H, LLerena A, López-López M.
Neurologia. 2018 Apr;33(3):165-176.
Interethnic relationships of CYP2D6 variants in native and Mestizo populations sharing the same ecosystem.
Perez-Paramo YX, Hernandez-Cabrera F, Dorado P, Llerena A, Muñoz-Jimenez S, Ortiz-Lopez R, Rojas-Martinez A.
Pharmacogenomics.2015;16(7):703-12.
Population pharmacogenetics of Ibero-Latinoamerican populations (MESTIFAR 2014).
Sosa-Macias M, Moya GE, LLerena A, Ramírez R, Terán E, Peñas-LLedó EM,Tarazona-Santos E, Galaviz-Hernández C, Céspedes-Garro C, Acosta H.
Pharmacogenomics. 2015;16(7):673-6.